Literature DB >> 15246454

Lower prefrontal gray matter volume in schizophrenia in chronic but not in first episode schizophrenia patients.

Vicente Molina1, Javier Sanz, Fernando Sarramea, Carlos Benito, Tomás Palomo.   

Abstract

Although a lower volume of prefrontal (PF) gray matter (GM) in patients with schizophrenia than in normal control subjects is a replicated finding, it is not yet clear whether this finding is present at the onset of illness. Clinical and imaging data suggest that the reduction in PF GM becomes apparent only some years following the onset of illness. To test this hypothesis, we used magnetic resonance imaging to study PF GM and sulcal cerebrospinal fluid (CSF) volumes in 81 schizophrenic patients. A Talairach-based tool was used for segmentation. Subjects included 44 healthy controls, 22 first-episode (FE), treatment-naïve patients with duration of illness of less than 1 year; 29 short-term chronic (SC) patients with durations of illness between 1.5 and 6 years; and 30 long-term chronic (LC) patients with duration of illness of more than 6 years. The data from healthy controls were used to calculate volume residuals in the patients, defined as deviations from the expected values given individual age and intracranial volume. The FE group did not show significant differences in GM or in CSF volumes compared with controls. However, both the SC and the LC patients showed the expected pattern of lower values for PF GM and an excess of PF sulcal CSF compared with controls. There were no significant differences between SC and LC patients in any of these measurements. There was a significant and inverse association between duration of illness and GM residuals. That association fit a nonlinear rather than a linear model, which was consistent with a decrease of GM volume during the first years following illness onset. No significant differences were found between those receiving atypical and typical antipsychotic drugs during the previous year.

Entities:  

Mesh:

Year:  2004        PMID: 15246454     DOI: 10.1016/j.pscychresns.2004.01.005

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  10 in total

1.  Dorsolateral prefrontal and superior temporal volume deficits in first-episode psychoses that evolve into schizophrenia.

Authors:  Vicente Molina; Javier Sanz; Fernando Sarramea; Rogelio Luque; Carlos Benito; Tomás Palomo
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-09-14       Impact factor: 5.270

2.  Progressive Brain Atrophy and Cortical Thinning in Schizophrenia after Commencing Clozapine Treatment.

Authors:  Mohamed Ahmed; Dara M Cannon; Cathy Scanlon; Laurena Holleran; Heike Schmidt; John McFarland; Camilla Langan; Peter McCarthy; Gareth J Barker; Brian Hallahan; Colm McDonald
Journal:  Neuropsychopharmacology       Date:  2015-04-01       Impact factor: 7.853

3.  Progressive and interrelated functional and structural evidence of post-onset brain reduction in schizophrenia.

Authors:  Dean F Salisbury; Noriomi Kuroki; Kiyoto Kasai; Martha E Shenton; Robert W McCarley
Journal:  Arch Gen Psychiatry       Date:  2007-05

4.  Association between brain-derived neurotrophic factor Val66Met gene polymorphism and progressive brain volume changes in schizophrenia.

Authors:  Beng-Choon Ho; Nancy C Andreasen; Jeffrey D Dawson; Thomas H Wassink
Journal:  Am J Psychiatry       Date:  2007-12       Impact factor: 18.112

5.  Long-acting injectable antipsychotics for first-episode schizophrenia: the pros and cons.

Authors:  Borah Kim; Sang-Hyuk Lee; Yen Kuang Yang; Jong-Il Park; Young-Chul Chung
Journal:  Schizophr Res Treatment       Date:  2012-08-14

6.  Age-related increase in the number of oligodendrocytes is dysregulated in schizophrenia and mood disorders.

Authors:  Victor Vostrikov; Natalya Uranova
Journal:  Schizophr Res Treatment       Date:  2011-07-03

7.  Visual imagery imitation skills and cognitive functions in patients with Schizophrenia.

Authors:  Makoto Tanaka; Takao Osanai; Takuhiko Kato; Hisako Ogasawara; Kazumaru Wada
Journal:  Hong Kong J Occup Ther       Date:  2022-05-28       Impact factor: 1.476

8.  Emotional decision-making and its dissociable components in schizophrenia and schizoaffective disorder: a behavioural and MRI investigation.

Authors:  Preethi Premkumar; Dominic Fannon; Elizabeth Kuipers; Andrew Simmons; Sophia Frangou; Veena Kumari
Journal:  Neuropsychologia       Date:  2008-02-07       Impact factor: 3.139

9.  Holistic Consideration of Patients with Schizophrenia to Improve Medication Adherence and Outcomes.

Authors:  Lan-Ting Lee; Kao Chin Chen; Wei Hung Chang; Po See Chen; I Hui Lee; Yen Kuang Yang
Journal:  Clin Psychopharmacol Neurosci       Date:  2015-08-31       Impact factor: 2.582

10.  Parahippocampal area three gray matter is reduced in first-episode schizophrenia spectrum: Discovery and replication samples.

Authors:  Mark T Curtis; Brian A Coffman; Dean F Salisbury
Journal:  Hum Brain Mapp       Date:  2020-11-21       Impact factor: 5.038

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.